Eli Lilly's tirzepatide is off FDA's shortage list
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
There's no playbook for how to be competitive in artificial intelligence (AI) as a big pharma company, but Eli Lilly (NYSE: LLY) is taking a shot at developing one. With the appointment of a new chief ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...
Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...
Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...
Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 ...
The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...
Best Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback